Erratum: Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
- PMID: 34285523
- PMCID: PMC8286780
- DOI: 10.2147/CEOR.S328284
Erratum: Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
Abstract
[This corrects the article DOI: 10.2147/CEOR.S302097.].
© 2021 Mareque et al.
Erratum for
-
Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain.Clinicoecon Outcomes Res. 2021 Apr 22;13:263-277. doi: 10.2147/CEOR.S302097. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 33911887 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
